RecruitingNot ApplicableNCT04115254

Stereotactic Magnetic Resonance Guided Radiation Therapy

A Master Protocol of Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy (SMART)


Sponsor

Dana-Farber Cancer Institute

Enrollment

397 participants

Start Date

Oct 22, 2019

Study Type

INTERVENTIONAL

Conditions

Summary

This is a master prospective Phase I-II trial evaluating feasibility and efficacy of stereotactic magnetic resonance (MR) guided adaptive radiation therapy (SMART) in patients with cancer. * The phase 1 study will evaluate the feasibility and safety of delivering SMART in patients with cancer. * Phase 2 will evaluate efficacy of SMART with specific reference to tumor control and improvement in patient reported outcome measures


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a radiation therapy technique called MR-guided SBRT (stereotactic body radiotherapy), which uses real-time MRI imaging to precisely target tumours during treatment. This allows radiation to be delivered more accurately while protecting nearby healthy tissue. **You may be eligible if...** - You have a confirmed cancer that requires stereotactic body radiation therapy (SBRT) - Your tumour is 7 cm or smaller - You are 18 years old or older - You are reasonably active and able to care for yourself (ECOG 0–2) - You are able to have an MRI scan **You may NOT be eligible if...** - You are allergic to gadolinium-based MRI contrast (if contrast will be used) - You are pregnant - You have severe claustrophobia or anxiety that prevents MRI - You cannot undergo an MRI for any reason Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATIONMR-guided Linac

Radiation will be delivered on an MR-guided Linear Accelerator


Locations(2)

Brigham & Women's Hospital

Boston, Massachusetts, United States

Dana Farber Cancer Institute

Boston, Massachusetts, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04115254


Related Trials